Floatz logo

Mtp-101C

Amyotrophic Lateral Sclerosis ALS

Duke UniversityCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

150 Active assets in the Amyotrophic Lateral Sclerosis ALS cohort.

Asset / SponsorPhaseRating
TAURURSODIOL
Amylyx Pharmaceuticals Inc.
Phase 3BBB
Tofersen
Biogen
Phase 4BBB
Riluzole
AB Science
Phase 4BB
Mexiletine
Bjorn Oskarsson, MD
Phase 4BB
DIACETYL(N(4)-METHYLTHIOSEMICARBAZONATO) COPPER (II)
Collaborative Medicinal Development Pty Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

Mtp-101C is also rated in:

Primary Sclerosing CholangitisDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →